Pentokey Organy

Who are the top shareholders of the Pentokey Organy?

The top shareholders of Pentokey Organy include Purshottam Kejriwal, who holds 35.72%, and ICICI Bank Limited, the largest public shareholder at 2.24%. Individual investors own 16.31% of the shares, with no pledged promoter holdings or foreign institutional investors involved.

The top shareholders of Pentokey Organy include the promoters, who hold the majority of the shares. The promoter with the highest holding is Purshottam Kejriwal, owning 35.72% of the company. Additionally, Icici Bank Limited is the highest public shareholder, holding 2.24%. Individual investors collectively hold 16.31% of the shares. There are no pledged promoter holdings, and currently, there are no foreign institutional investors (FIIs) involved with the company.

What does Pentokey Organy do?

Pentokey Organy (India) Ltd is a micro-cap company trading in pharmaceutical products within the commodity chemicals sector, with recent net sales of 1 Cr and a market cap of Rs 26 Cr. It has a P/E ratio of 26.00 and a return on equity of 2.75%.

Overview: <BR>Pentokey Organy (India) Ltd is engaged in the trading of pharmaceutical products within the commodity chemicals industry and operates in the micro-cap market.<BR><BR>History: <BR>The company was incorporated on November 26, 1986. The latest quarterly results reported are for March 2025, showing net sales and net profit figures.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 1 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 26 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 26.00 <BR>Industry P/E: 47 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.52 <BR>Return on Equity: 2.75% <BR>Price to Book: 2.75<BR><BR>Contact Details: <BR>Address: 509 Western Edge I Western edg, Express Highway warehouse Mumbai Maharashtra : 400066 <BR>Email: investors@pentokey.com <BR>Website: http://www.pentokey.com

What is the bonus history of the Pentokey Organy?

Pentokey Organy's bonus history includes a significant event on December 13, 2012, when it announced a bonus issue in a 2:3 ratio, granting shareholders two additional shares for every three shares held, with a record date of December 14, 2012.

Pentokey Organy has a bonus history that includes a notable event on December 13, 2012. The company announced a bonus issue in a ratio of 2:3, with the record date set for December 14, 2012. This means that for every three shares held, shareholders received two additional shares as a bonus. If you have any more questions about the company or its financial activities, feel free to ask!

Has Pentokey Organy declared dividend?

Pentokey Organy (India) Ltd has declared a 10% dividend, amounting to ₹1 per share, with an ex-date of August 5, 2013. Despite this, the dividend yield is 0%, and total returns have shown significant price growth over the 4 and 5-year periods, despite no dividends in recent years.

Pentokey Organy (India) Ltd has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 1<BR>- Ex-date: 05 Aug 13<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6 Months period, the price return was -16.45%, the dividend return was 0%, resulting in a total return of -16.45%.<BR><BR>For the 1 Year period, the price return was -1.12%, the dividend return was 0%, leading to a total return of -1.12%.<BR><BR>During the 2 Years period, the price return was -5.62%, the dividend return was 0%, which resulted in a total return of -5.62%.<BR><BR>In the 3 Years period, the price return was 0%, the dividend return was 0%, yielding a total return of 0.0%.<BR><BR>Over the 4 Years period, the price return was 123.0%, the dividend return was 0%, culminating in a total return of 123.0%.<BR><BR>For the 5 Years period, the price return was 621.74%, the dividend return was 0%, resulting in a total return of 621.74%.<BR><BR>Overall, while Pentokey Organy has declared a dividend, the dividend yield remains at 0%. The total returns indicate significant price growth over longer periods, particularly in the 4 and 5-year spans, despite the absence of dividends in recent years.

Who are the peers of the Pentokey Organy?

Pentokey Organy's peers include Tata Chemicals, Chemplast Sanmar, GHCL, India Glycols, Fischer Medical, Hind.Fluoro Carb, Jayshree Chem., Sreechem Resins, and Advance Petroch. In terms of management risk, Pentokey Organy is rated below average, with a 1-year return of 6.92%, significantly lower than India Glycols' 150.85% but higher than Hind.Fluoro Carb's -25.51%.

Peers: The peers of Pentokey Organy are Tata Chemicals, Chemplast Sanmar, GHCL, India Glycols, Fischer Medical, Hind.Fluoro Carb, Jayshree Chem., Sreechem Resins, and Advance Petroch.<BR><BR>Quality Snapshot: Excellent management risk is observed at GHCL and Sreechem Resins, while Good management risk is found at Chemplast Sanmar. Average management risk is present at Tata Chemicals, India Glycols, and Advance Petroch, while Below Average management risk is noted at Pentokey Organy, Fischer Medical, Jayshree Chem., and the rest. Hind.Fluoro Carb does not qualify for management risk assessment. In terms of Growth, Excellent capital structure is noted at GHCL, while Average capital structure is seen at Tata Chemicals, Sreechem Resins, and the rest. Below Average capital structure is present at Chemplast Sanmar, India Glycols, Pentokey Organy, Jayshree Chem., Fischer Medical, and Advance Petroch.<BR><BR>Return Snapshot: India Glycols has the highest 1-year return at 150.85%, while Hind.Fluoro Carb has the lowest at -25.51%. Pentokey Organy's 1-year return of 6.92% is significantly lower than that of India Glycols but higher than that of Hind.Fluoro Carb. Additionally, the six-month returns are negative for Tata Chemicals, Chemplast Sanmar, Hind.Fluoro Carb, Jayshree Chem., Sreechem Resins, and Advance Petroch.

What is the technical trend for Pentokey Organy?

As of May 28, 2025, Pentokey Organy's trend is mildly bearish, with mixed signals from MACD and Bollinger Bands, while daily moving averages indicate a bearish stance.

As of 28 May 2025, the technical trend for Pentokey Organy has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD remains bearish. The Bollinger Bands also reflect a mildly bullish trend on the weekly chart but are bearish on the monthly. The daily moving averages are bearish, and the KST shows a bullish signal on the weekly but bearish on the monthly. Dow Theory suggests a mildly bearish trend on the weekly, with no clear trend on the monthly. Overall, the current stance is mildly bearish, influenced primarily by the daily moving averages and the mixed signals from the MACD and Bollinger Bands.

Who are in the management team of Pentokey Organy?

As of March 2022, the management team of Pentokey Organy includes Devendra J Shrimanker, Prajakta Shidhore, Arun Goenka, Purusottam Kejriwal, Divya Desai, and Kostuv Kejriwal, who oversee operations and ensure regulatory compliance.

As of March 2022, the management team of Pentokey Organy includes the following individuals:<BR><BR>1. Devendra J Shrimanker - Independent Director<BR>2. Prajakta Shidhore - Independent Director<BR>3. Arun Goenka - Director<BR>4. Purusottam Kejriwal - Director<BR>5. Divya Desai - Company Secretary & Compliance Officer<BR>6. Kostuv Kejriwal - Director<BR><BR>This team is responsible for overseeing the company's operations and ensuring compliance with regulations.

How big is Pentokey Organy?

As of 24th July, Pentokey Organy (India) Ltd has a market capitalization of 26.00 Cr, with net sales of 4579.16 Cr and a net profit of 133.62 Cr for the latest four quarters. Shareholder's funds are reported at 9.26 Cr and total assets at 9.51 Cr as of March 2024.

As of 24th July, Pentokey Organy (India) Ltd has a market capitalization of 26.00 Cr, categorizing it as a Micro Cap company.<BR><BR>For the latest four quarters, the sum of Net Sales is 4579.16 Cr, while the sum of Net Profit stands at 133.62 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, with Shareholder's Funds reported at 9.26 Cr and Total Assets at 9.51 Cr.

Is Pentokey Organy overvalued or undervalued?

As of August 12, 2025, Pentokey Organy is considered very expensive and overvalued, with a PE ratio of 28.07 and a return of -16.96% over the past year, despite a strong 5-year return of 719.60%.

As of 12 August 2025, the valuation grade for Pentokey Organy has moved from risky to very expensive, indicating a significant shift in its perceived value. The company is currently considered overvalued. Key ratios include a PE ratio of 28.07, an EV to EBITDA of 23.18, and a PEG ratio of 0.78, which suggests that despite a relatively low growth expectation, the stock price is high compared to its earnings potential.<BR><BR>In comparison with peers, Solar Industries has a much higher PE ratio of 104.56, while Gujarat Fluoroch stands at 60.59, both indicating that Pentokey Organy is priced lower than some competitors but still categorized as very expensive. Notably, the company's return over the past year is -16.96%, contrasting sharply with its 5-year return of 719.60%, which may suggest volatility and investor sentiment challenges. Overall, the current valuation metrics and peer comparisons reinforce the conclusion that Pentokey Organy is overvalued in the current market context.

Are Pentokey Organy latest results good or bad?

Pentokey Organy's latest results are concerning, reporting zero revenue in FY25, a 100% decline from previous years, despite a clean balance sheet. While there was a significant increase in net sales and profit in the most recent quarter, the lack of consistent revenue generation raises doubts about the company's operational viability.

Pentokey Organy's latest results indicate a concerning situation for the company. In FY25, the company reported zero revenue, marking a dramatic decline of 100% year-over-year from ₹4.00 crores in both FY24 and FY23. This cessation of commercial activities raises significant concerns about the company's operational viability and strategic direction.<BR><BR>While the company maintains a clean balance sheet with zero debt and shareholder funds of ₹9.46 crores, the complete absence of revenue generation is alarming. The stock has experienced extreme volatility, with a remarkable long-term return of 882.67% over five years, but it has also declined 8.41% over the past two years, reflecting investor uncertainty.<BR><BR>In the most recent quarterly results for September 2025, there was a notable increase in net sales and net profit compared to the same quarter in the previous year, with net sales growing by 345.45% and net profit increasing by 27.27%. However, this improvement comes after a period of operational dormancy, and it remains to be seen whether this trend can be sustained.<BR><BR>Overall, the company's financial performance is characterized by operational inactivity, making the latest results appear bad in the context of its historical performance and current market expectations. Investors should approach with caution, given the significant uncertainties surrounding its future operations.

How has been the historical performance of Pentokey Organy?

Pentokey Organy has experienced significant financial fluctuations, with net sales declining from 9.29 Cr in Mar'19 to 0.83 Cr in Mar'25, and profits dropping sharply from 3.18 Cr in Mar'23 to 0.25 Cr in Mar'25, despite an increase in total assets and liabilities. Overall, the company faces a challenging financial trajectory marked by declining revenues and profits.

Answer:<BR>The historical performance of Pentokey Organy shows significant fluctuations in its financial metrics over the years.<BR><BR>Breakdown:<BR>Pentokey Organy's net sales have seen a decline from 9.29 Cr in Mar'19 to just 0.83 Cr in Mar'25, with a notable drop in the last two years. The total operating income followed a similar trend, peaking at 4.40 Cr in Mar'24 before falling to 0.83 Cr in Mar'25. The company's total expenditure, excluding depreciation, also decreased from 10.14 Cr in Mar'19 to 1.04 Cr in Mar'25. Operating profit (PBDIT) showed a positive trend until Mar'23, reaching 3.21 Cr, but then fell to 0.25 Cr in Mar'25. Profit before tax and profit after tax mirrored this decline, with both metrics at 0.25 Cr in Mar'25, down from 3.18 Cr in Mar'23. The company's total assets increased from 6.09 Cr in Mar'20 to 9.79 Cr in Mar'25, while total liabilities rose from 5.51 Cr to 9.79 Cr in the same period. Cash flow metrics indicate no significant inflow or outflow, remaining at zero across the years. Overall, Pentokey Organy has experienced a challenging financial trajectory, with fluctuating revenues and profits, alongside a gradual increase in assets and liabilities.

When is the next results date for Pentokey Organy (India) Ltd?

The next results date for Pentokey Organy (India) Ltd is 30 May 2026.

The next results date for Pentokey Organy (India) Ltd is scheduled for 30 May 2026.

Should I buy, sell or hold Pentokey Organy (India) Ltd?

Which are the latest news on Pentokey Organy?

Why is Pentokey Organy (India) Ltd falling/rising?

As of 03-Jun, Pentokey Organy (India) Ltd's stock price is Rs 37.75, down 6.97% with significant volatility and underperformance against benchmarks. Despite increased investor participation, the stock shows a bearish trend with declines over various periods.

As of 03-Jun, Pentokey Organy (India) Ltd's stock price is falling, currently at Rs 37.75, reflecting a decrease of Rs 2.83 or 6.97%. This decline is evident in the stock's performance over various periods, including a 1-week drop of 2.83% and a 1-month decrease of 9.82%. Year-to-date, the stock has fallen by 7.00%, and over the past year, it has decreased by 12.51%. <BR><BR>Despite opening with a significant gain of 17.77% today, the stock experienced high volatility, reaching an intraday high of Rs 47.79 before dropping to a low of Rs 36.81, which represents a decline of 9.29% from its peak. The overall performance today has underperformed the sector by 7.3%. Additionally, while the stock is trading above its 5-day and 50-day moving averages, it remains below the 20-day, 100-day, and 200-day moving averages, indicating a bearish trend. <BR><BR>Investor participation has increased, with a delivery volume rise of 139.02% compared to the 5-day average, but this has not translated into a positive price movement. The stock's liquidity remains adequate for trading, but the combination of high volatility and underperformance against benchmarks suggests that the stock is currently in a downward trajectory.